Table 1 Clinicopathological correlation of TSPAN15 expression in OSCC
Clinical features | Cases | TSPAN15 expression | P value | |
|---|---|---|---|---|
Low group (%) | High group (%) | |||
Age(years old) | 0.388 | |||
≤59 | 131 | 78 (59.5%) | 53 (40.5%) | |
>59 | 135 | 73 (54.1%) | 62 (45.9%) | |
Gender | 0.323 | |||
Male | 148 | 80 (54.1%) | 68 (45.9%) | |
Female | 118 | 71 (60.2%) | 47 (39.8%) | |
Location | 0.245 | |||
Upper | 63 | 30 (47.6%) | 33 (52.4%) | |
Middle | 183 | 109 (59.6%) | 74 (40.4%) | |
Lower | 20 | 12 (60.0%) | 8 (40.0%) | |
Differentiation | 0.421 | |||
Grade 1 | 63 | 39 (61.9%) | 24 (38.1%) | |
Grade 2 | 134 | 77 (57.5%) | 57 (42.5%) | |
Grade 3 | 69 | 35 (69.6%) | 34 (30.4%) | |
LN metastasis | <0.001 | |||
N0 | 149 | 102 (68.5%) | 47 (31.5%) | |
N1 | 117 | 49 (41.9%) | 68 (58.1%) | |
Distant metastasis | 0.003 | |||
M0 | 256 | 150 (58.6%) | 106 (41.4%) | |
M1 | 10 | 1 (10.0%) | 9 (90.0%) | |
Clinical stage | 0.001 | |||
Early (I−II) | 177 | 111 (62.7%) | 66 (37.3%) | |
Advanced (III−IV) | 89 | 40 (44.9%) | 49 (55.1%) | |
